Takeda Pharmaceutical revenue and financials
Secondary listing. The primary listing is Takeda Pharmaceutical · TSE (JPY)
$18.10Change from previous close: +1.63%Absolute change: +$0.29
In the fiscal year ended March 2026, Takeda Pharmaceutical reported revenue of ¥4.51T (−1.66% year over year). The net loss was ¥152.39B.
Fiscal year ending in March. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- −1.66%
- FY to Mar 2026 vs FY to Mar 2025
- Net margin
- -3.4%
- FY to Mar 2025: 2.4%
Financial data
Amounts in millions of JPY; per-share values in JPY; shares in millions.
| Item | FY to Mar 2026 | FY to Mar 2025 | FY to Mar 2024 | FY to Mar 2023 | FY to Mar 2022 | FY to Mar 2021 | FY to Mar 2020 | FY to Mar 2019 | FY to Mar 2018 | FY to Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 15,511,506 | 14,248,344 | 15,108,792 | 13,957,750 | 13,178,018 | 12,912,293 | 12,821,094 | 13,792,773 | 4,106,463 | — |
| Current assets | 3,090,503 | 2,521,192 | 2,558,580 | 2,397,956 | 2,593,642 | 2,712,893 | 2,469,432 | 2,993,037 | 1,078,808 | — |
| Cash and equivalents | 595,054 | 385,113 | 457,800 | 533,530 | 849,695 | 966,222 | 637,614 | 702,093 | 294,522 | 319,455 |
| Short-term investments | 41,888 | 20,476 | 15,089 | 20,174 | — | — | — | — | — | — |
| Receivables | 876,348 | 725,254 | 697,610 | 681,694 | — | — | — | — | — | — |
| Inventory | 1,396,620 | 1,217,349 | 1,209,869 | 986,457 | — | — | — | — | — | — |
| Net property, plant and equipment | 2,120,639 | 1,968,209 | 1,989,777 | 1,691,229 | — | — | — | — | — | — |
| Goodwill | 5,809,010 | 5,324,430 | 5,410,067 | 4,790,723 | 4,407,749 | 4,033,917 | 4,012,528 | 4,240,251 | 1,029,248 | — |
| Other intangible assets | 3,419,348 | 3,631,560 | 4,274,683 | 4,269,657 | — | — | — | — | — | — |
| Long-term investments | 448,737 | 361,926 | 430,608 | 378,857 | — | — | — | — | — | — |
| Current liabilities | 2,832,074 | 2,506,521 | 2,313,103 | 2,481,940 | 2,145,730 | 1,773,176 | 2,175,898 | 2,553,049 | 737,509 | — |
| Accounts payable | 324,368 | 308,450 | 319,955 | 307,453 | — | — | — | — | — | — |
| Long-term debt | 4,369,681 | 4,515,265 | 4,843,752 | 4,382,341 | 4,345,410 | 4,635,371 | 5,093,304 | 5,750,951 | 985,662 | — |
| Total debt | 4,881,838 | 4,515,265 | 4,843,752 | 4,382,341 | — | — | — | — | — | — |
| Total liabilities | 8,080,857 | 7,312,365 | 7,834,788 | 7,603,078 | 7,494,495 | 7,735,116 | 8,093,608 | 8,606,782 | 2,089,054 | — |
| Total equity (incl. minority) | 7,430,649 | 6,935,979 | 7,274,005 | 6,354,671 | — | — | — | — | — | — |
| Retained earnings | 712,381 | 1,187,586 | 1,391,203 | 1,541,146 | — | — | — | — | — | — |
| Minority interest | 1,208 | 895 | 741 | 549 | — | — | — | — | — | — |